Stockreport

Avidity Biosciences to Present New AOC 1001 Long-term Efficacy and Safety Data from MARINA-OLE™ Trial in People Living with Myotonic Dystrophy Type 1 (DM1) at 2024 Muscular Dystrophy Assoc...

Avidity Biosciences, Inc.  (RNA) 
PDF and a principal investigator in END-DM1, ongoing natural history study will join Avidity management to present data from MARINA-OLE ™ Avidity to host Volume 8 of inves [Read more]